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Clinical Research
A Randomized Controlled Trial of Allopurinol in Patients With
Peripheral Arterial Disease
Alan J. Robertson, MD, and Allan D. Struthers, MD
Division of Cardiovascular and Diabetes Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom
See editorial by Verma and Gin, pages 145-147 of this issue.
ABSTRACT
Background: Patients with peripheral arterial disease (PAD) are
limited by intermittent claudication in the distance they can walk.
Allopurinol has been shown in coronary arterial disease to prolong
exercise before angina occurs, likely by prevention of oxygen wastage
in tissues and reduction of harmful oxidative stress.
Methods: In this study we evaluated whether allopurinol could prolong
the time to development of leg pain in participants with PAD. In a
double-blind, randomized controlled clinical trial participants were
randomized to receive either allopurinol 300 mg twice daily or placebo
for 6 months. The primary outcome was change in exercise capacity on
treadmill testing at 6 months. Secondary outcomes were 6-minute
walking distance, Walking Impairment Questionnaire, SF-36 ques-
tionnaire, ﬂow-mediated dilatation, and oxidized low-density lipopro-
tein. Outcome measures were repeated midstudy and at the end of
study. The mean age of the 50 participants was 68.4  1.2 years with
RESUME
Introduction : Les patients atteints d’unemaladie arterielle peripherique
(MAP) sont limites par une claudication intermittente dans la distance
qu’ils peuvent parcourir. Il a ete demontre que lors de maladie coro-
narienne l’allopurinol prolonge la periode d’exercice avant que n’appar-
aisse l’angine, probablement par la prevention des pertes d’oxygènedans
les tissus et la reduction des effets nefastes du stress oxydatif.
Methodes : Dans cette etude, nous avons evalue si l’allopurinol
pourrait prolonger la duree avant la manifestation de la douleur à la
jambe chez les participants atteints de MAP. Les participants d’un
essai clinique à repartition aleatoire et à double insu etaient repartis
de manière aleatoire pour recevoir soit l’allopurinol à raison de 300
mg 2 fois par jour ou le placebo durant 6 mois. Le principal critère de
jugement etait la modiﬁcation de la capacite d’effort à l’epreuve de
marche sur tapis roulant à 6 mois. Les critères secondaires etaient la
distance de marche en 6 minutes, le Walking Impairment Question-
Peripheral arterial disease (PAD) is a disease that carries with it
signiﬁcant morbidity and through links with cardiovascular
disease, mortality. The total disease prevalence has been esti-
mated at 3%-10%, increasing with age to 15%-20% in those
older than 70 years of age.1,2 However, much of this disease is
asymptomatic, as demonstrated by the Edinburgh Artery
Study.3 Patients with major asymptomatic disease had a 60%
increase in relative risk of cardiovascular disease.3 The
cornerstone of treatment of PAD therefore remains identiﬁ-
cation and treatment of cardiovascular risk factors, however,
from a patient perspective the most troubling problem re-
mains that of intermittent claudication.4
An inevitable consequence of normal intracellular meta-
bolism is the production of reactive oxygen species.5 Of
particular relevance is the production of hydrogen peroxide
and superoxide. This happens as a by-product of the
formation of uric acid by xanthine oxidoreductase (XOR) and
thus blockade of this process might be beneﬁcial in reducing
the endothelial dysfunction caused by reactive oxygen species.
Allopurinol is a well-established drug that is highly effective in
blocking XOR and reducing uric acid levels. It is therefore a
mainstay of the preventive treatment of gout but has shown
some promise in a number of cardiovascular conditions; most
recently de Abajo et al.6 showed in a case-control study that
allopurinol use (in particular at higher doses and for longer
periods) was associated with a lower risk of non-fatal
myocardial infarction.6-10 However, the most striking symp-
tomatic effect has been that demonstrated by Noman et al. in
patients with angina: their study of 65 patients with angio-
graphically documented coronary artery disease, a positive
exercise tolerance test, and stable chronic angina pectoris
demonstrated an almost one-ﬁfth improvement in time to ST
depression, time to development of chest pain, and total ex-
ercise time.9
This antianginal effect raises questions about its potential
mechanism. One of these could be that oxygen is a substrate
for XOR and hence XOR blockade with allopurinol might
boost tissue oxygen and thus promote an oxygen-sparing ef-
fect. If this were the case, one would postulate that allopurinol
might exert an anti-ischemic effect in PAD. However, the
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other possible mechanism of this anti-anginal effect is that of
an ofﬂoading effect on the heart. It is known that patients
with angina beneﬁt from drugs that reduce afterload on the
heart, because this decreases the oxygen demand of the heart,
thereby improving the oxygen supply/demand ratio. Rekhraj
et al. showed that allopurinol was capable of achieving this
ofﬂoading effect by reducing end-systolic volume, however, if
this is the primary mechanism of action it would not apply in
PAD and hence there would be no beneﬁt in PAD.8 We
conducted this study to help answer this mechanistic
question.
The aim of this randomized controlled trial was to examine
whether high-dose allopurinol prolongs exercise duration in
patients with PAD.
Methods
This study was a randomized, double-blind parallel-group
placebo-controlled clinical trial, run in accordance with the
Declaration of Helsinki and The Medicines for Human Use
(Clinical Trials) (Amendment) Regulations, 2006. Approvals
were received from local National Health Service (NHS)
Research and Development, Scotland A Research Ethics
Committee, University of Dundee/NHS Tayside (as
cosponsor), and the Medicines and Healthcare Products
Regulatory Agency (MHRA). The study was registered with
the International Standard Randomised Controlled Trial
Number (ISRCTN01772998), ClinicalTrials.gov
(NCT01147705), and EudraCT (2010-020662-23).
Patients were recruited after their attendance at the Inter-
mittent Claudication Clinic at Ninewells Hospital, Dundee.
Where patients met the inclusion/exclusion criteria (Table 1)
on the basis of their clinic letter a covering letter was sent out
from the clinician they had seen in clinic, enclosing a
Participant Information Sheet and a prepaid reply slip. All
those who replied and indicated they would be interested in
participating in the study were telephoned by A.J.R. Missing
information relevant to inclusion/exclusion criteria was
checked in this phone call and then patients were offered an
appointment for an initial screening visit.
All study visits were conducted at the Department of
Clinical Pharmacology, Ninewells Hospital, Dundee, between
March 2011 and June 2012. After written informed consent,
an initial clinical assessment was undertaken before baseline
exercise testing and phlebotomy. At the second visit a repeat
treadmill test was carried out to check for reproducibilitydif
Table 1. Inclusion/exclusion criteria
Inclusion  Men and women age 35-85 years of age who suffer from PAD
 PAD deﬁned as:
B Claudication deﬁned as leg pain with walking that disappears within 10 minutes with standing and of presumed atherosclerotic origin and
B An ankle brachial pressure index of < 0.90 on the worst leg at rest
 Stable disease demonstrated by a reproducible pain-free walking distance on 2 consecutive treadmill tests (ie, less than 25% variance)
 The reason for termination of the test must be claudication pain only
Exclusion  Rest pain
 Childbearing potential without adequate contraceptive measures
 Heart failure or any other exercise-limiting cardiac disease
 Blood pressure > 180/100 mm Hg
 Renal or liver disease
 Malignancy
 Already receiving allopurinol or had an adverse reaction to it
 Recent marked change in symptoms or recent (in the past 6 months) intervention for PAD
 Receiving treatment with either 6-mercaptopurine, azathioprine, warfarin, or theophylline
PAD, peripheral arterial disease.
39 of 50 (78%) male.
Results: Five participants withdrew during the study (2 active, 3 pla-
cebo). There was a signiﬁcant reduction in uric acid levels in those who
received active treatment of 52.1% (P < 0.001), but no signiﬁcant
change in either the pain-free or the maximum walking distance. Other
measures of exercise capacity, blood vessel function, and the partici-
pants’ own assessment of their health and walking ability also did not
change during the course of the study.
Conclusions: Although allopurinol has been shown to be of beneﬁt in a
number of other diseases, in this study there was no evidence of any
improvement after treatment in patients with PAD.
naire, le questionnaire SF-36, la dilatation mediee par le ﬂux et les
oxydes lipoproteines de faible densite. Les mesures des resultats
etaient repetees à la mi-etude et à la ﬁn de l’etude. Cinquante par-
ticipants dont 39 (78 %) etaient des hommes avaient un âge moyen
de 68,4  1,2 ans.
Resultats : Cinq participants se sont retires durant l’etude (2 du
groupe sous traitement actif, 3 du groupe sous placebo). Une reduction
signiﬁcative des concentrations en acide urique de 52,1 % (P < 0,001)
a ete observee chez ceux qui recevaient le traitement actif, mais aucun
changement signiﬁcatif n’a ete observe dans la distance de marche
sans douleur ou maximale. Les autres mesures de la capacite d’effort,
le fonctionnement des vaisseaux sanguins et la propre evaluation des
participants concernant leur sante et leur habilete à la marche n’ont
egalement pas change au cours de l’etude.
Conclusions : Bien qu’il ait ete demontre que l’allopurinol est
beneﬁque contre plusieurs autres maladies, cette etude n’a montre
aucune preuve d’amelioration après le traitement chez les patients
atteints de MAP.
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variance was < 25% then baseline measurements of the
outcome measures described herein were carried out and
participants were provided with an initial supply of the
investigational medicinal product (IMP).
Randomization had been carried out by Tayside Pharma-
ceuticals (Ninewells Hospital, Dundee) as supplier of the
IMP, before commencement of study visits. This was achieved
via a computer-generated randomization system using 5
blocks of 10 to ensure equal numbers between active and
placebo groups. The IMP supply was sequentially numbered
and the randomization key held in sealed envelopes by Tay-
side Pharmaceuticals, Ninewells Pharmacy (in case of any
need for emergency unblinding), and for safe-keeping in a
locked ﬁreproof cabinet by the Asthma & Allergy Research
Group, Ninewells. The investigating team did not have access
to the key until after analysis had taken place.
Participants were randomized to receive either allopurinol
or placebo for the 6 months of participation. The initial dose
was 100 mg once daily of allopurinol (or placebo) for 2 weeks,
increased to 300 mg once daily for 4 weeks, then continued at
300 mg twice daily for the remainder of the study.
Exercise tolerance testing (ETT) was conducted using the
Gardner protocol, as is common in PAD studies to test efﬁ-
cacy of new treatments.11,12 The machine used was a GE
Marquette Series 2000 Treadmill Stress Testing System (GE
Healthcare Clinical Systems [UK] Ltd, Hatﬁeld, UK). The
tests were conducted in accordance with the University of
Dundee standard operating procedures for ETT and were
supervised by A.J.R. (Principal Investigator and Advanced Life
Support instructor) and a second member of staff.
Six-minute walk tests (6MWTs) were carried out as per
American Thoracic Society guidelines, in a quiet corridor on a
30-m track marked at 1-m intervals.13
Endothelial function was assessed by measuring ﬂow-
mediated dilatation (FMD) of the brachial artery. FMD
was measured using a Sequoia 512 (Siemens, Camberley,
UK) ultrasound machine with an 8-MHz linear array probe.
Our standard departmental protocol was used to carry out
the measurements, which is based on the International
Brachial Artery Reactivity Task Force guidelines.14 The
FMD was analyzed using a Brachial Analyzer for Research,
part of the Medical Imaging Applications Vascular Research
Tools software suite (version 5.6.12, Medical Imaging Ap-
plications LLC, Coralville, IA), again using our departmental
protocol. The acquisition and analysis of the FMD images
were performed by A.J.R., who was blinded to the allocated
treatment.
Blinded analysis of oxidized low-density lipoprotein
(Ox-LDL), a plasma marker of oxidative stress, was carried out
by the Vascular and Inﬂammatory Diseases Research Unit in
Ninewells Hospital, Dundee, using a Mercodia Oxidised-
LDL enzyme-linked immunosorbent assay.
The Walking Impairment Questionnaire (WIQ) is a short
and straightforward questionnaire widely used in the evaluation
of PAD patient symptoms, which provides good correlation
with patient performance on the treadmill, especially when
patients are stratiﬁed into high and low performance
groups.15-19 The SF-36 is a multipurpose, short-form health
survey consisting of 36 questions that provide summary mea-
sures for functional health and well-being and a
psychometrically-based physical and mental health summary.20
A meta-analysis of exercise treatment trials in PAD and
several drug trials was initially used to guide the required
power for the study. In randomized trials in PAD, the stan-
dard deviation (SD) tends to be approximately 30 metres.21-24
In drug treatment trials, the time to claudication usually in-
creases by approximately 30 metres (on average 30% more
than placebo).21-24 A 30-m improvement is thought to make a
clinically signiﬁcant difference in PAD. If it is assumed a 30-
metre improvement with a 30-metre SD, then 42 subjects
total in a parallel group study would be required to demon-
strate a 30-metre improvement over placebo (for 90% power
at P < 0.05). However to allow for dropouts, 50 PAD sub-
jects were enrolled in this study.
Analysis was undertaken using IBM SPSS Statistics version
20 (IBM Corp, Armonk, NY). Data were checked for
normality using the Shapiro-Wilk test (because of the smaller
sample sizes involved in this study). Where the signiﬁcance
value of the Shapiro-Wilk test was < 0.05 the data were
assumed to be nonnormally distributed. In these situations it
was log-transformed to see if this led to a normal distribution,
thus allowing parametric analysis to be carried out. If it
remained nonnormally distributed then nonparametric anal-
ysis was used. Pearson c2 was used for discrete variables. An
independent samples t test was used for normally distributed
continuous variables and a Mann-Whitney U test for
nonparametric data. For repeated comparisons within the
same subject, a paired t test was used for normally distributed
data and a Wilcoxon signed-rank matched pairs test for
nonparametric data. A 2-factor analysis of variance with
repeated measures on 1 factor was also used for the primary
end points.
The primary end point was the change in distance
walked on an exercise tolerance test from baseline over a 6-
month period. This comprised the claudication onset dis-
tance (COD: when the participant ﬁrst noticed claudication
pain) and the peak walking distance (PWD: when they
could walk no further and had to terminate the treadmill
test).
The overall secondary objectives were to: (1) see if allo-
purinol improved the quality of life in patients with PAD; and
(2) to investigate the antioxidant effects of allopurinol in pa-
tients with PAD. To that end there were a number of sec-
ondary end points, namely the aforementioned 6MWT,
WIQ/SF-36 questionnaires, FMD, and Ox-LDL.
Results
In total, 50 patients were recruited, 5 withdrew during the
course of the study (allopurinol, n ¼ 2; placebo, n ¼ 3;
Fig. 1). Of the 50 patients randomized, 78% (39 of 50) were
male. Participants had a mean age of 68.4  1.2 years. The
baseline demographic characteristics were as outlined in
Table 2.
Uric acid levels were checked at the initial and ﬁnal visits,
which provided a good idea of concordance with treatment.
As noted in Table 2, there was no signiﬁcant difference in
baseline uric acid levels between the 2 groups (P ¼ 0.98).
There was a highly signiﬁcant decrease in uric acid for those
who received treatment, with an order of magnitude of 52.1%
(P < 0.001; Fig. 2). A small 10.0% decrease was noted in
the placebo group but this was not statistically signiﬁcant
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(P ¼ 0.06). All other participants in the active treatment arm
had > 13% reduction, with most a 40%-60% reduction as
indicated by the aforementioned mean.
The baseline, midpoint, and end of study treadmill values
for the COD and PWD are shown in Table 3. Two-factor
analysis of variance analysis showed no signiﬁcant difference
between the 2 groups over time with P ¼ 0.35 (COD) and
P ¼ 0.75 (PWD).
No signiﬁcant difference in the 6MWT distances were
noted between the 2 arms of the study, as shown in Table 4.
Baseline FMD measurements were similar in the 2 groups,
with no signiﬁcant changes noted over the course of treatment
(Table 5).
Baseline WIQ scores were 132.9 (95% conﬁdence interval
[CI], 108.7-157.1) in the allopurinol group and 140.0 (95%
CI, 111.1-168.8) in the placebo group (P ¼ 0.92). By the end
of the study these had not signiﬁcantly changed, with values of
139.7 (95% CI, 96.2-183.2) and 146.1 (95% CI, 111.8-
180.3), respectively (P ¼ 0.34). Subdivision into the distance,
speed, and climb elements showed similar results.
Baseline SF-36 scores were 535.1 (95% CI, 457.7-612.5)
in the allopurinol group and 571.0 (95% CI, 519.5-622.4) in
the placebo group (P ¼ 0.73). Values at the ﬁnal visit were
555.2 (95% CI, 485.0-625.5) and 536.5 (95% CI, 470.8-
602.2), respectively (P ¼ 0.57). Analysis of the various sub-
domains of SF-36 also showed no signiﬁcant difference.
Baseline Ox-LDL values were 53.0 U/L in the allopurinol
group (95% CI, 45.7-60.3) and 49.4 U/L (95% CI, 43.1-
55.8) in the placebo group (P ¼ 0.62). These did not
signiﬁcantly change during the course of the study.
There was 1 serious adverse event (community-acquired
pneumonia requiring hospital admission). No signiﬁcant
changes in urea and electrolytes or liver function tests were
noted in the course of the study in either group.
Figure 1. Consolidated Standards of Reporting Trials diagram.
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Discussion
There was no signiﬁcant difference in baseline COD and
PWD measurements in the placebo group (despite a greater
pack-year history in this group). By the end of the study both
measures had increased in each armof the studydthis was on the
order of 40 m for COD and 27 m for PWD, again with no
signiﬁcant difference between active and placebo groups. This
temporal increase in walking distance in the placebo arm is
something that has been recognized previously in studies of
PAD.25 To investigate if there was any subgroup that showed
beneﬁt from allopurinol, the treadmill results were split into
those with high/low baseline COD/PWD and those with high/
low baseline uric acid/systolic blood pressure and ankle-brachial
index (see Supplementary Material). None of these subdivisions
changed the results and there remained no statistically signiﬁcant
difference between the 2 groups after 6 months of treatment.
In consideration of the FMD results, it can be seen that the
baseline values were similar in the active and placebo groups.
The relative change in vessel diameter after hyperemia (ie,
after blood pressure cuff deﬂation) was very slightly better in
the allopurinol group, however, the absolute level was still very
small (< 0.5%) and the difference between the active and
placebo groups was not statistically signiﬁcant. Although these
ﬁndings are in keeping with other outcome measures in this
trial, a number of other studies of allopurinol have previously
shown an improvement in FMD.8 In one other recent study
of allopurinol by Szwejkowski et al. no effect on endothelial
function was found. They postulated that the lack of effect on
FMD results in their study might be because baseline FMD
was high with little room for further improvement. This
might be that their patients with type II diabetes mellitus were
very well treated with statins, angiotensin-converting enzyme
inhibitors, and angiotensin receptor blockersdall of which are
known to improve endothelial function.7 Prescription of these
agents was reassuringly high also in this population of PAD
patients (see Table 2), however it also has to be considered
that the patient population studied, all with proven PAD, had
stiffer vessels that were less likely to respond to treatment.26,27
We know that allopurinol has been shown to be of beneﬁt
in angina, in some ways a similar disease process, yet in this
study it has not been of beneﬁt in patients with PAD. Rekhraj
et al showed that allopurinol reduced left ventricular (LV)
end-systolic volume and LV afterload (measured using the
augmentation index) in patients with ischemic heart disease,
which suggests that ofﬂoading the left ventricle might be
another mechanism that contributes to the anti-ischemic ef-
fect of allopurinol in angina pectoris.8 This particular effect on
LV afterload would produce an anti-ischemic effect on the
heart but not an anti-ischemic effect in PAD. Our negative
ﬁnding in PAD therefore implies that the mechanism of ac-
tion of allopurinol in angina is its LV ofﬂoading effect and not
a direct oxygen-sparing effect by blocking an oxidase enzyme
that “wastes” tissue oxygen.
With PAD a factor might also be a different calibre of
vessel. The coronary arteries at their largest (the left main
Table 3. Treadmill walking distance in metres at different study
stages
Time point Allopurinol (95% CI) Placebo (95% CI) P
COD baseline 137.1 (82.0-192.2) 151.7 (105.4-198.0) 0.31
COD visit 4 161.7 (109.0-214.3) 155.0 (110.2-200.0) 0.95
COD visit 6 180.0 (111.5-248.6) 177.1 (133.1-221.2) 0.48
PWD baseline 315.5 (206.0-425.0) 362.6 (266.4-458.8) 0.24
PWD visit 4 320.1 (209.0-431.2) 341.5 (256.9-426.1) 0.42
PWD visit 6 347.4 (224.8-470.0) 358.4 (253.9-462.9) 0.61
CI, conﬁdence interval; COD, claudication onset distance; PWD, peak
walking distance.
Table 4. Six-minute walk test distance in metres at different study
stages
Time point Allopurinol (95% CI) Placebo (95% CI) P
Baseline 401.2 (371.7-430.7) 389.1 (369.2-409.1) 0.72
Visit 4 396.3 (366.1-426.6) 395.6 (376.3-414.8) 0.97
Visit 6 398.2 (374.4-422.1) 399.9 (375.8-424.0) 0.92
Mean change from
baseline to Visit 4
4.4 (10.5 to 19.4) 8.7 (2.4-19.8) 0.73
Mean change from
baseline to Visit 6
6.4 (3.9 to 16.6) 13.1 (1.0-25.1) 0.63
CI, conﬁdence interval.
Table 2. Characteristics of participants at baseline
Allopurinol
(n ¼ 25)
Placebo
(n ¼ 25) P
Mean age, years 69.6 (9.1) 67.3 (7.5) 0.34
Male sex, n (%) 21 (84) 18 (72) 0.50
Height, m 1.69 (0.09) 1.66 (0.07) 0.28
Weight, kg 77.7 (16.6) 80.6 (16.6) 0.36
BMI 27.2 (5.1) 29.1 (5.2) 0.21
Pulse, beats per minute 76.5 (11.6) 75.4 (14.9) 0.62
Pack-years 31.7 (21.0) 49.7 (37.0) 0.04
Systolic BP, mm Hg 153 (21) 156 (20) 0.65
Diastolic BP, mm Hg 76 (11) 79 (10) 0.27
ABI 0.61 (0.12) 0.60 (0.12) 0.65
Average weekly alcohol intake
(units per week)
7.4 (10.0) 16.8 (18.8) 0.08
Smoking status
Current smoker 6 7 0.75
Ex- or nonsmoker 19 18
Uric acid, mmol/L 0.36 (0.09) 0.34 (0.09) 0.98
Concomitant medications, n (%)
Aspirin/clopidogrel 24 (96) 23 (92) 0.88
Statin 23 (92) 24 (96) 0.88
ACEi/ARB 17 (68) 18 (72) 0.87
Data are presented as mean (SD) except where otherwise noted.
ABI, ankle-brachial index; ACEi, angiotensin-converting enzyme inhibi-
tor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood
pressure.
Figure 2. Reduction in uric acid (vertical bars indicate 95% conﬁ-
dence interval).
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stem) measure 4.5  0.5 mm, and decreases to 1.9  0.4 mm
in the distal left anterior descending artery.28 In comparison,
the peripheral arteries in the legs are more than twice this
diameterdwith the common femoral artery having a diameter
of 9.3  1.1 mm, and decreases to 4.9  0.6 mm when it
reaches the distal popliteal artery.29 However, the extent to
which this is a true comparison is unknown, because in the
later stages of PAD much of the lower limb supply is via
collateral vessels, which might in fact be of a smaller calibre
than coronary vessels.
This study was based in a single centre, with a relatively
small number of participants in absolute terms. Two partici-
pants had either no change or an increase in uric acid level
between start and end of the study (which suggests at least a
period of noncompliance), however, in general the IMP was
well tolerated with only a small number of adverse events
reported. There were issues in consistent assessment of the
COD with treadmill testing because of the variation between
participants in their reporting of paindsome would forget to
mention it and only volunteer the information with
prompting. There was also a clear heterogeneity in the par-
ticipants with regard to severity of PADdsome managed to
walk only 1 or 2 minutes on the treadmill before having to
stop because of pain, yet others were able to manage a much
more considerable distance. In some respects this could be
seen as a limitation, however, in reality it reﬂects the clinical
spectrum of PAD. Attempts were made in the analysis to
subdivide the participants into ‘poor’ and ‘good’ walkers with
regard to COD and PWD; it could be argued that this sub-
division reduced the number available for analysis by too great
a degree (the study was certainly not powered for such com-
parisons), and that greater number of participants (or a focus
on particularly good or poor walkers) could have been bene-
ﬁcial, however, there did not appear to be any trend that
would have reached statistical signiﬁcance with a greater
number of participants.
With regard to the 6MWT there is an element of a
‘learning effect’ at play. This is something that has been
recognized previously and is believed to be on the order of
approximately 4.5% in healthy subjects, possibly greater in
those with more disease burden.30 It tends to decrease with
repeated test administration, plateauing after 3 tests.31 In this
study, 3 tests were carried out (baseline/mid/end). Only a
small learning effect of approximately 3% appeared to be
present but an increased number of tests would have helped to
reduce the effect of this. This would, however, have to be
balanced by the fatigue experienced by patientsdadditional
walking tests would have either necessitated extra study visits
or a much increased visit length to allow for sufﬁcient rest,
potentially reducing the acceptability of the study protocol to
participants.
In conclusion, treatment with allopurinol did not prolong
exercise duration in patients with PAD. All other measures of
exercise, vascular health, and indeed the participants’ own
assessment of their health according to questionnaire re-
sponses did not change.
In view of the excellent reduction in uric acid levels in the
allopurinol group this would suggest that it is the treatment
itself that does not work in this particular disease process
rather than a failure to properly block XOR. This study once
again underscores that despite there being many effective
antianginal therapies, in general these are of little beneﬁt in
PAD.
As highlighted at the beginning of this article, there were 2
potential mechanisms at play for how allopurinol has shown
beneﬁt in cardiac ischemiadeither by reduction of oxygen
wastage to the tissues or via ofﬂoading the heart. Because of
the conclusively negative results in PAD presented herein,
they suggest that LV ofﬂoading is the main mechanism un-
derlying the antianginal effect of allopurinol.
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